Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells
Authors
Keywords
-
Journal
CANCER SCIENCE
Volume 103, Issue 9, Pages 1665-1671
Publisher
Wiley
Online
2012-06-18
DOI
10.1111/j.1349-7006.2012.02359.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
- (2011) Marianne E Pavel et al. LANCET
- Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
- (2010) Guy Jerusalem et al. BREAST CANCER RESEARCH AND TREATMENT
- Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up
- (2010) Lisa Rydén et al. BREAST CANCER RESEARCH AND TREATMENT
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- (2010) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL INVESTIGATION
- Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
- (2010) Marco Colleoni et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast Cancer Subtypes and the Risk of Local and Regional Relapse
- (2010) K. David Voduc et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
- (2010) Darcy A. Krueger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes
- (2010) J. H. Taube et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab
- (2009) S. Gori et al. ANNALS OF ONCOLOGY
- Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
- (2009) B. T. Hennessy et al. CANCER RESEARCH
- mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary
- (2009) S. Mabuchi et al. CLINICAL CANCER RESEARCH
- AKT/mTOR Pathway Activation and BCL-2 Family Proteins Modulate the Sensitivity of Human Small Cell Lung Cancer Cells to RAD001
- (2009) M. Marinov et al. CLINICAL CANCER RESEARCH
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer
- (2009) Aye Aye Thike et al. MODERN PATHOLOGY
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- (2009) Rafael Rosell et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
- (2008) Sendurai A. Mani et al. CELL
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Basal carcinoma of the breast revisited: an old entity with new interpretations
- (2008) E Korsching et al. JOURNAL OF CLINICAL PATHOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now